Stay updated with breaking news from Absci. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Absci Corp (NASDAQ:ABSI – Get Rating)’s stock price was down 11.2% during trading on Monday . The stock traded as low as $7.30 and last traded at $7.41. Approximately 8,172 shares were traded during trading, a decline of 100% from the average daily volume of 1,677,830 shares. The stock had previously closed at $8.34. Several […]
VANCOUVER, Wash., March 21, 2022 -- Absci Corporation , the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins,... | March 21, 2022
By Colin Kellaher Shares of Absci Corp. surged more than 50% in premarket trading Friday after the drug and target discovery company said it formed a research collaboration potentially worth... | January 7, 2022
Absci Announces Research Collaboration with Merck Collaboration to leverage Absci's Deep Learning-Enabled Drug Creation™ and Bionic Protein™... | January 7, 2022
AbSci Announces Strategic Investment by Merck Global Health Innovation Fund News provided by Share this article Share this article VANCOUVER, Wash., Feb. 22, 2021 /PRNewswire/ -- AbSci, a pioneering synthetic biology company that unifies biologic drug discovery and development processes, today announced a strategic equity investment by Merck Global Health Innovation Fund (Merck GHI) and potential discovery collaborations with Merck Research Laboratories. AbSci founder and CEO Sean McClain said, "It has been terrific to work with Merck on many levels. We are pleased to be able to add value an...